Cerebral amyloid angiopathy (CAA) is a type of age-related cerebral angiopathy with progressive deposition of ß-amyloid proteins in the leptomeningeal and cortical vasculature. Apart from being a major cause of spontaneous lobar cerebral hemorrhage in the elderly population, CAA is also an important contributor for vascular cognitive impairment and a frequent concomitant pathology in Alzheimer’s disease. The clinical impact of CAA has never been more relevant as CAA has been identified an intersect between cerebrovascular and neurodegenerative processes. It has been shown that CAA comprises heterogenous presentations and severities, but research regarding its early detection, disease staging and specific phenotyping are lacking. The therapeutic approach is also very limited as we do not currently own a disease modifying treatment. To facilitate our diagnosis could help for precise enrollment of research participants and improve our knowledge on its pathogenic mechanism, which are both fundamental basis for developing potential therapeutics in preventing or slowing the disease from progression.
In this research topic, the major goal is to improve the clinical CAA diagnosis in terms of developing more refined approaches in heterogenous settings, and to delineate its roles in Alzheimer’s disease and neurodegeneration. In addition, we aim to collect both basic and clinical research articles in CAA that will expand our current understanding of its pathophysiological mechanisms, potential new biomarkers, and novel therapeutic targets.
• Characterization of CAA with different phenotypes
• Diagnosis of CAA in early disease stage
• Novel structural, molecular and functional imaging study in CAA
• Body fluid or new biomarkers in CAA, including imaging biomarkers such as PET and MRI.
• Epidemiological study in CAA
• CAA in Alzheimer’s disease and other neurodegenerative disorders
• Basic or clinical study investigating potential therapeutic approach in CAA
Please note that while basic or clinical research studies will be considered, mechanistic studies of animal models are considered out of the scope of this collection.
Cerebral amyloid angiopathy (CAA) is a type of age-related cerebral angiopathy with progressive deposition of ß-amyloid proteins in the leptomeningeal and cortical vasculature. Apart from being a major cause of spontaneous lobar cerebral hemorrhage in the elderly population, CAA is also an important contributor for vascular cognitive impairment and a frequent concomitant pathology in Alzheimer’s disease. The clinical impact of CAA has never been more relevant as CAA has been identified an intersect between cerebrovascular and neurodegenerative processes. It has been shown that CAA comprises heterogenous presentations and severities, but research regarding its early detection, disease staging and specific phenotyping are lacking. The therapeutic approach is also very limited as we do not currently own a disease modifying treatment. To facilitate our diagnosis could help for precise enrollment of research participants and improve our knowledge on its pathogenic mechanism, which are both fundamental basis for developing potential therapeutics in preventing or slowing the disease from progression.
In this research topic, the major goal is to improve the clinical CAA diagnosis in terms of developing more refined approaches in heterogenous settings, and to delineate its roles in Alzheimer’s disease and neurodegeneration. In addition, we aim to collect both basic and clinical research articles in CAA that will expand our current understanding of its pathophysiological mechanisms, potential new biomarkers, and novel therapeutic targets.
• Characterization of CAA with different phenotypes
• Diagnosis of CAA in early disease stage
• Novel structural, molecular and functional imaging study in CAA
• Body fluid or new biomarkers in CAA, including imaging biomarkers such as PET and MRI.
• Epidemiological study in CAA
• CAA in Alzheimer’s disease and other neurodegenerative disorders
• Basic or clinical study investigating potential therapeutic approach in CAA
Please note that while basic or clinical research studies will be considered, mechanistic studies of animal models are considered out of the scope of this collection.
